Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
FGF23
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "FGF23" in MCE Product Catalog:
6
6 Publications Verification
Synonyms: Iron(III) citrate; Zerenex
Research Areas:
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .
2
1
Target:
Research Areas:
Cat. No.: HY-150687
CAS No.: 1010888-06-8
Target:
Research Areas:
ZINC12409120 is a high selective ERK inhibitor. ZINC12409120 acts on disrupting FGF23:α-Klotho interaction to inhibit ERK activity with an IC50 of 5.0 μM .
Target:
Research Areas:
T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC50=7 μM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream) .
Cat. No.: HY-RS04900
Target:
Research Areas:
FGF23 Human Pre-designed siRNA Set A contains three designed siRNAs for FGF23 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23171
Target:
Research Areas:
Fgf23 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fgf23 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-173191
CAS No.: 2760404-50-8
Target:
Research Areas:
SK-124 is an orally active salt-inducible kinase (SIK) inhibitor with an IC50 of 230 nM against SIK1, 4.1 nM against SIK2, and 21 nM against SIK3, exhibiting excellent kinome selectivity . SK-124 blocks SIK-mediated CRTC2 phosphorylation, promotes CRTC2 nuclear translocation, and regulates vitamin D metabolism by upregulating renal Cyp27b1 and downregulating Cyp24a1 . SK-124 upregulates the expression of bone-related genes, increases serum Ca 2+, 1,25-vitamin D and intact FGF23 levels, and suppresses endogenous PTH levels . SK-124 can be used in studies related to osteoporosis, male osteoporosis, and chronic kidney disease-mineral and bone disorder .
Cat. No.: HY-W012856
CAS No.: 620-14-4
Synonyms: 3-Methylethylbenzene
Cat. No.: HY-RS16734
Target:
Research Areas:
Fgf23 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgf23 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-183371
CAS No.: 864868-22-4
Target:
Research Areas:
ZINC13407541 is a fibroblast growth factor 23 (FGF23) antagonist with an IC50 of 0.45 μM. ZINC13407541 preferentially binds to the FGF23:FGFR interface to disrupt their protein-protein interactions. ZINC13407541 can be used for the research of hypophosphatemia .
Cat. No.: HY-P700493
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FGF-23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
Species:
Source:
Cat. No.: HY-P700064AF
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FGF-23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
Cat. No.: HY-P702509
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ADHR; FGF23; FGF-23; fibroblast growth factor 23; HPDR2; HYPF; phosphatonin; PHPTC; tumor-derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor
Cat. No.: HY-186173
CAS No.: 2314337-87-4
Research Areas:
MD-3-A45 is an inhibitor of fibroblast growth factor 23 (FGF-23). MD-3-A45 blocks the activation of the FGFRs/α-klotho signaling pathway by FGF-23 and inhibits FGF-23-induced ERK activation. MD-3-A45 can be used in the research of chronic kidney disease, hereditary hypophosphatemic rickets and acquired hypophosphatemic rickets .
Cat. No.: HY-159978
CAS No.: 1628848-73-6
Target:
Research Areas:
EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
